 SALT LAKE CITY, Nov. 11, 2020 GLOBE NEWSWIRE -- At the annual meeting of the American College of Rheumatology ACR, Myriad Genetics, Inc. NASDAQ: MYGN, a leader in molecular diagnostics and precision medicine, shared new data further demonstrating that Vectra testing and three additional biomarkers, combined with traditional risk factors, can predict the risk of cardiovascular CV events in patients with rheumatoid arthritis RA. Also, presented at the meeting was a study showing that Vectra is a significant predictor for joint damage, and is a better predictor than several tested subjective measures. Vectra is an advanced blood test that objectively measures inflammation caused by RA. 